According to the research report, the global pharmaceutical CDMO market size is expected to touch USD 172.02Billion by 2032, from USD 94.17Billion in 2022, growing with a significant CAGR of 6.21% from 2023 to 2032.
Key Takeaways:
- By Product, the API segment dominated the market with the largest market share in 2022. However, the drug product is expected to increase in the expected time period.
- By Workflow, the commercial segments had the largest market share in the Pharmaceutical CDMO market in the anticipated timeframe. Additionally, the clinical segment is the fast-growing segment in the Pharmaceutical CDMO market in the predicted period.
- By Application, the oncology segment accounted for the largest market in the anticipated time period with the largest market revenue. Cardiovascular diseases and diabetes is one the largest emerging segment in the forecast period.
- By Region, Asia-pacific had the largest market in terms of market size in 2022. Regions like North America and Europe are emerging as growing regions in the Pharmaceutical CDMO market.
The pharmaceutical CDMO report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global pharmaceutical CDMO in conjunction with the geographical landscape of this vertical have also been included in this report.
The report offers intricate dynamics about different aspects of the global pharmaceutical CDMO market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global pharmaceutical CDMO during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).
Sample Link @ https://www.precedenceresearch.com/sample/2936
Report Scope of the Pharmaceutical CDMO Market:
| Report Coverage | Details |
| Market Size in 2023 | USD 100.02 Billion |
| Market Size by 2032 | USD 172.02 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 6.21% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Product, By Drug Product, By Dosage Form, By Indication, and By End-User |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
This study covers a detailed segmentation of the global pharmaceutical CDMO market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global pharmaceutical CDMO market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.
Key Players
- Bushu Pharmaceuticals Ltd.
- Nipro Corporation
- Thermo Fisher Scientific Inc.
- Samsung Biologics
- Laboratory Corporation of America Holdings
- Siegfried Holding Ag
- Catalent, Inc
- Lonza Group AG
- Recipharm Ab
- Piramal Pharma Solutions
- Cordenpharma International
- Cambrex Corporation
- Wuxi Apptec
Market Segmentation
By Product
- API
- By Synthetic
- Solid
- Liquid
- By Type
- Traditional Active Pharmaceutical Ingredient (Traditional API)
- Highly Potent Active Pharmaceutical Ingredient (HP-API)
- Antibody Drug Conjugate (ADC)
- Others
- By Drug
- Innovative
- Generics
- By Manufacturing
- Continuous manufacturing
- Batch manufacturing
- Biotech
- By Synthetic
By Drug Product
- Oral Solid Dose
- Semi-solid dose
- Liquid Dose
- Others
By Dosage Form
- Solid
- Tablets
- Capsules
- Powder
- Semi-Solid
- Cream
- Paste
- Gel
- Liquid Dose Formulation
- Injectables
- Sterile Vials
- Single Use/Single Dose
- Multi-Use
- Ampules
- Prefilled Syringes
- Suspension
- Emulsion
- Gas Dose Formulation
- Inhaler
- Aerosols
By Indication
- Cancer
- Cardiovascular Disease
- Diabetes
- Pain
- Respiratory disease
- Other Disease
By End-User
- Big Pharmaceutical Companies
- Small & Medium-Sized Pharmaceutical Companies
- Generic Pharmaceutical Companies
- Other End Users
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Research Methodology
The research methodology adopted by analysts for compiling the global pharmaceutical CDMO report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global pharmaceutical CDMO market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Pharmaceutical CDMO Market
5.1. COVID-19 Landscape: Pharmaceutical CDMO Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Pharmaceutical CDMO Market, By Product
8.1. Pharmaceutical CDMO Market, by Product, 2023-2032
8.1.1. API
8.1.1.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Pharmaceutical CDMO Market, By Drug Product
9.1. Pharmaceutical CDMO Market, by Drug Product, 2023-2032
9.1.1. Oral Solid Dose
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Semi-solid dose
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Liquid Dose
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Pharmaceutical CDMO Market, By Dosage Form
10.1. Pharmaceutical CDMO Market, by Dosage Form, 2023-2032
10.1.1. Solid
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Semi-Solid
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Liquid Dose Formulation
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Gas Dose Formulation
10.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Pharmaceutical CDMO Market, By Indication
11.1. Pharmaceutical CDMO Market, by Indication, 2023-2032
11.1.1. Cancer
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Cardiovascular Disease
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Diabetes
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Pain
11.1.4.1. Market Revenue and Forecast (2020-2032)
11.1.5. Respiratory disease
11.1.5.1. Market Revenue and Forecast (2020-2032)
11.1.6. Other Disease
11.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Pharmaceutical CDMO Market, By End-User
12.1. Pharmaceutical CDMO Market, by End-User, 2023-2032
12.1.1. Big Pharmaceutical Companies
12.1.1.1. Market Revenue and Forecast (2020-2032)
12.1.2. Small & Medium-Sized Pharmaceutical Companies
12.1.2.1. Market Revenue and Forecast (2020-2032)
12.1.3. Generic Pharmaceutical Companies
12.1.3.1. Market Revenue and Forecast (2020-2032)
12.1.4. Other End Users
12.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 13. Global Pharmaceutical CDMO Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Product (2020-2032)
13.1.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.1.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.1.4. Market Revenue and Forecast, by Indication (2020-2032)
13.1.5. Market Revenue and Forecast, by End-User (2020-2032)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.1.6.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.1.6.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.1.6.4. Market Revenue and Forecast, by Indication (2020-2032)
13.1.6.5. Market Revenue and Forecast, by End-User (2020-2032)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Product (2020-2032)
13.1.7.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.1.7.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.1.7.4. Market Revenue and Forecast, by Indication (2020-2032)
13.1.7.5. Market Revenue and Forecast, by End-User (2020-2032)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.2.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.2.4. Market Revenue and Forecast, by Indication (2020-2032)
13.2.5. Market Revenue and Forecast, by End-User (2020-2032)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.6.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.2.6.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.2.7. Market Revenue and Forecast, by Indication (2020-2032)
13.2.8. Market Revenue and Forecast, by End-User (2020-2032)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.9.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.2.9.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.2.10. Market Revenue and Forecast, by Indication (2020-2032)
13.2.11. Market Revenue and Forecast, by End-User (2020-2032)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.12.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.2.12.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.2.12.4. Market Revenue and Forecast, by Indication (2020-2032)
13.2.13. Market Revenue and Forecast, by End-User (2020-2032)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.14.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.2.14.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.2.14.4. Market Revenue and Forecast, by Indication (2020-2032)
13.2.15. Market Revenue and Forecast, by End-User (2020-2032)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.3.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.3.4. Market Revenue and Forecast, by Indication (2020-2032)
13.3.5. Market Revenue and Forecast, by End-User (2020-2032)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.6.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.3.6.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.3.6.4. Market Revenue and Forecast, by Indication (2020-2032)
13.3.7. Market Revenue and Forecast, by End-User (2020-2032)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.8.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.3.8.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.3.8.4. Market Revenue and Forecast, by Indication (2020-2032)
13.3.9. Market Revenue and Forecast, by End-User (2020-2032)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.10.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.3.10.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.3.10.4. Market Revenue and Forecast, by Indication (2020-2032)
13.3.10.5. Market Revenue and Forecast, by End-User (2020-2032)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.11.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.3.11.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.3.11.4. Market Revenue and Forecast, by Indication (2020-2032)
13.3.11.5. Market Revenue and Forecast, by End-User (2020-2032)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.4.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.4.4. Market Revenue and Forecast, by Indication (2020-2032)
13.4.5. Market Revenue and Forecast, by End-User (2020-2032)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.6.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.4.6.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.4.6.4. Market Revenue and Forecast, by Indication (2020-2032)
13.4.7. Market Revenue and Forecast, by End-User (2020-2032)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.8.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.4.8.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.4.8.4. Market Revenue and Forecast, by Indication (2020-2032)
13.4.9. Market Revenue and Forecast, by End-User (2020-2032)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.10.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.4.10.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.4.10.4. Market Revenue and Forecast, by Indication (2020-2032)
13.4.10.5. Market Revenue and Forecast, by End-User (2020-2032)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.11.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.4.11.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.4.11.4. Market Revenue and Forecast, by Indication (2020-2032)
13.4.11.5. Market Revenue and Forecast, by End-User (2020-2032)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product (2020-2032)
13.5.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.5.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.5.4. Market Revenue and Forecast, by Indication (2020-2032)
13.5.5. Market Revenue and Forecast, by End-User (2020-2032)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.5.6.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.5.6.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.5.6.4. Market Revenue and Forecast, by Indication (2020-2032)
13.5.7. Market Revenue and Forecast, by End-User (2020-2032)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Product (2020-2032)
13.5.8.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.5.8.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.5.8.4. Market Revenue and Forecast, by Indication (2020-2032)
13.5.8.5. Market Revenue and Forecast, by End-User (2020-2032)
Chapter 14. Company Profiles
14.1. Bushu Pharmaceuticals Ltd.
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Nipro Corporation
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Thermo Fisher Scientific Inc.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Samsung Biologics
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Laboratory Corporation of America Holdings
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Siegfried Holding Ag
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Catalent, Inc
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Lonza Group AG
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Recipharm Ab
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Piramal Pharma Solutions
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments